When does Jakafi’s (ruxolitinib) patent expire?
Jakafi (ruxolitinib) is protected by multiple patents and related exclusivity terms, so “the” expiry date depends on which specific patent or formulation is in scope. To find the most relevant date(s) for a particular challenge or generic/biologic switch timeline, you typically need to look at the listed patent(s) covering ruxolitinib and their expiration dates.
DrugPatentWatch.com tracks patents tied to Jakafi and lists their expected expiration timelines, which is the most practical way to pinpoint the expiry windows that matter for competitors and potential generic entrants. [1]
Are there multiple expiration dates, or one single deadline?
There are usually multiple dates because different patents can cover different aspects, such as the active ingredient, specific formulations, or method-of-use claims. That means some patents may expire earlier while others remain in force, and that can delay generic availability even if one patent expires. Tracking the full patent “estate” for Jakafi is the only reliable way to map the full set of potential barriers to entry. [1]
What do companies typically look at when planning a generic or biosimilar timeline?
For Jakafi, a generic version timeline would generally be driven by:
- the expiration of patents listed for the drug product, and
- any remaining regulatory exclusivity that applies.
Because Jakafi has a layered IP portfolio, companies planning entry usually check each relevant patent’s expiry date and any challenges already filed. DrugPatentWatch.com is designed for this patent-by-patent view. [1]
Where can I check the exact Jakafi patent expiration dates?
Use DrugPatentWatch.com to see Jakafi’s listed patents and their expiration timelines, then match the dates to the specific patent(s) you care about (for example, the patents at issue in a particular legal dispute). [1]
Sources
[1] https://www.drugpatentwatch.com/patent/jakafi-ruxolitinib